SANTA ANA, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 4^th Great Bay Cell and Gene Therapy Forum, taking place September 22-23, 2026, in Guangzhou, China.